Want to see DHR full AI Analyst Report?
Top Page
Danaher
(NYSE:DHR)
Select Model
Select Model
Rating:69Neutral
Price Target:
$193.00
▼(-0.90% Downside)
Action:Reiterated
Date:06/04/26
The score is primarily driven by strong cash flow generation and solid margins with manageable leverage, reinforced by a generally positive earnings-call outlook (raised EPS guidance and strong free cash flow) despite near-term headwinds. Offsetting these positives are a weaker technical setup (below key longer-term moving averages with negative MACD) and a relatively expensive valuation (P/E ~33.8 with a low dividend yield).
Positive Factors
Robust cash generation
Sustained high operating and free cash flow provides durable internal funding for R&D, consumables capacity, share actions and M&A without overreliance on external markets. Strong cash conversion improves resilience to cyclical revenue swings and supports multi-year strategic investments.
Negative Factors
China diagnostics pricing headwinds
Volume-based procurement and reimbursement changes in China represent structural policy risk that can durably compress revenue and margins in Diagnostics. Given China’s scale, sustained policy-driven pricing pressure could lower regional earnings and slow global segment recovery for quarters to years.
Read all positive and negative factors
Positive Factors
Negative Factors
Robust cash generation
Sustained high operating and free cash flow provides durable internal funding for R&D, consumables capacity, share actions and M&A without overreliance on external markets. Strong cash conversion improves resilience to cyclical revenue swings and supports multi-year strategic investments.
Read all positive factors
Danaher Key Performance Indicators (KPIs)
Any
Revenue by Geography
Breaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Breaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Data provided by:
The Fly
The FlyDanaher (DHR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$125.40B
Dividend Yield0.53%
Average Volume (3M)4.48M
Price to Earnings (P/E)34.0
Beta (1Y)0.82
Revenue Growth4.02%
EPS Growth0.05%
CountryUS
Employees61,000
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)5.19
Shares Outstanding707,770,600
10 Day Avg. Volume3,791,785
30 Day Avg. Volume4,482,200
Financial Highlights & Ratios
PEG Ratio-9.26
Price to Book (P/B)3.08
Price to Sales (P/S)6.59
P/FCF Ratio30.78
Enterprise Value/Market Cap1.11
Enterprise Value/Revenue5.60
Enterprise Value/Gross Profit9.22
Enterprise Value/Ebitda20.87
Forecast
1Y Price Target
$228.80Price Target Upside17.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering22
EPS Forecast (FY)8.44
Revenue Forecast (FY)$25.54B
Danaher Business Overview & Revenue Model
Company Description
Danaher Corporation is a diversified global technology and science company that specializes in developing, manufacturing, and distributing a wide array of professional, medical, industrial, and commercial products and services across the world. Th...
How the Company Makes Money
Danaher makes money primarily by selling products and services across its Biotechnology and Diagnostics businesses. In Biotechnology, revenue is generated from tools and consumables used in bioprocessing (e.g., filtration, chromatography, single-u...
Danaher Earnings Call Summary
Earnings Call Date:Apr 21, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Jul 21, 2026
Earnings Call Sentiment Positive
The call highlighted solid execution: strong earnings growth (+9.5% adjusted EPS), margin expansion, robust free cash flow, a raised full-year EPS range, clear momentum in bioprocessing (consumables growth and >30% equipment order growth), and constructive China trends. Management acknowledged near-term headwinds—chiefly a ~25% drop in respiratory revenue, Diagnostics weakness in China from VBP/reimbursement, and seasonally lower Q2 margins—but provided unchanged core revenue guidance (3%–6%), articulated remediation (DBS and identified Masimo synergies), and emphasized balance sheet strength and active M&A. Overall, positives (earnings, cash generation, bioprocessing momentum, product wins, M&A synergies) materially outweigh the moderated but manageable negatives (respiratory seasonality, China policy headwinds and instrument softness).Positive Updates
Revenue and Top-Line
Sales were $6.0 billion in Q1 2026; core revenue was up 0.5% year-over-year, with the rest of the business (ex-respiratory) growing ~3% year-over-year after a ~2.5% headwind from a lighter respiratory season.
Negative Updates
Respiratory Revenue Weakness
Cepheid respiratory revenue declined approximately 25% year-over-year in Q1 due to a lighter-than-typical seasonal respiratory season, creating a ~2.5% headwind to core revenue for the quarter.
Read all updates
Q1-2026 Updates
Positive
Negative
Revenue and Top-Line
Sales were $6.0 billion in Q1 2026; core revenue was up 0.5% year-over-year, with the rest of the business (ex-respiratory) growing ~3% year-over-year after a ~2.5% headwind from a lighter respiratory season.
Read all positive updates
Company Guidance
Danaher reiterated full‑year 2026 core revenue guidance of 3%–6% and raised adjusted diluted net EPS to $8.35–$8.55 (from $8.35–$8.50), assuming a slightly lower respiratory revenue outlook of ~$1.6–$1.7 billion; they expect Q2 core revenue to be up low single digits with an adjusted operating profit margin of ~26.5%. In Q1 the company reported $6.0 billion of sales, core revenue +0.5% (including a 2.5% headwind from respiratory), gross margin of 60.3%, adjusted operating margin of 30.2% (up 60 bps), adjusted EPS of $2.06 (+9.5%), $1.1 billion of free cash flow (105% FCF-to-net‑income conversion), and management expects >$5 billion of free cash flow for 2026; they said roughly a ~300‑basis‑point headwind (China diagnostics, respiratory and Life Sciences comps) should abate by year‑end, enabling an exit to mid‑single‑digit core growth, and noted the pending Masimo deal is expected to be accretive in the first full year and deliver high‑single‑digit ROIC by year five.Danaher Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
74
Positive
Cash Flow
81
Very Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 24.78B | 24.57B | 23.88B | 23.89B | 26.64B | 29.45B |
| Gross Profit | 15.04B | 14.97B | 14.21B | 14.03B | 16.19B | 17.95B |
| EBITDA | 6.64B | 6.95B | 7.28B | 7.50B | 9.48B | 10.01B |
| Net Income | 3.69B | 3.61B | 3.90B | 4.76B | 7.21B | 6.43B |
Balance Sheet | ||||||
| Total Assets | 83.54B | 83.46B | 77.54B | 84.49B | 84.35B | 83.18B |
| Cash, Cash Equivalents and Short-Term Investments | 5.70B | 4.62B | 2.08B | 5.86B | 6.00B | 2.59B |
| Total Debt | 18.48B | 18.42B | 17.15B | 19.54B | 20.62B | 23.27B |
| Total Liabilities | 30.59B | 30.93B | 27.99B | 31.00B | 34.26B | 38.01B |
| Stockholders Equity | 52.95B | 52.53B | 49.54B | 53.49B | 50.08B | 45.17B |
Cash Flow | ||||||
| Free Cash Flow | 5.29B | 5.26B | 5.30B | 5.78B | 7.37B | 7.06B |
| Operating Cash Flow | 6.44B | 6.42B | 6.69B | 7.16B | 8.52B | 8.36B |
| Investing Cash Flow | -1.20B | -1.20B | -1.98B | -7.08B | -2.23B | -12.99B |
| Financing Cash Flow | -1.66B | -2.96B | -8.38B | -273.00M | -2.57B | 1.29B |
Danaher Technical Analysis
Positive
194.75
Price Trends
178.27
Positive
188.27
Positive
203.10
Negative
Market Momentum
3.84
Negative
63.10
Neutral
77.55
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DHR, the sentiment is Positive. The current price of 194.75 is above the 20-day moving average (MA) of 184.46, above the 50-day MA of 178.27, and below the 200-day MA of 203.10, indicating a neutral trend. The MACD of 3.84 indicates Negative momentum. The RSI at 63.10 is Neutral, neither overbought nor oversold. The STOCH value of 77.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DHR.
Danaher Risk Analysis
Danaher disclosed 42 risk factors in its most recent earnings report. Danaher reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Danaher Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $42.41B | 39.33 | 70.87% | ― | 13.08% | 25.40% | |
71 Outperform | $35.89B | 25.43 | 20.84% | 0.72% | 9.11% | 22.77% | |
69 Neutral | $125.40B | 34.00 | 7.06% | 0.53% | 4.02% | 0.05% | |
69 Neutral | $34.90B | 64.99 | 8.04% | ― | 26.39% | -28.79% | |
67 Neutral | $172.66B | 25.20 | 13.26% | 0.30% | 5.36% | 6.54% | |
64 Neutral | $26.28B | 30.43 | -610.32% | ― | 6.78% | 6.19% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
DHR
Danaher
193.72
-7.30
-3.63%
A
Agilent
133.39
13.69
11.44%
IDXX
Idexx Laboratories
537.58
-5.13
-0.95%
MTD
Mettler-Toledo
1,300.38
94.73
7.86%
TMO
Thermo Fisher
513.33
87.12
20.44%
WAT
Waters
378.13
26.21
7.45%
Danaher Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Danaher Completes Multi-Tranche Swiss Franc Notes Offering
Positive
Jun 3, 2026
On June 3, 2026, Danaher and its wholly owned subsidiary DH Masi Finance Inc. completed a private placement of senior unsecured notes totaling CHF 2.38 billion to institutional accredited investors, with maturities ranging from 2031 to 2056 and fi...
Executive/Board ChangesShareholder Meetings
Danaher Shareholders Back Directors, Pay Plan and Auditor
Positive
May 7, 2026
At Danaher Corporation’s annual meeting of shareholders held on May 5, 2026, investors elected eleven directors to serve terms expiring in 2027, with each nominee receiving substantial majority support. Shareholders also ratified Ernst Youn...
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
Danaher Issues Euro Notes to Finance Masimo Acquisition
Positive
Apr 29, 2026
On April 29, 2026, Danaher issued €3 billion in euro-denominated senior notes across four tranches, including floating-rate notes due 2028 and fixed-rate notes maturing between 2030 and 2038, as general unsecured senior indebtedness under it...
Business Operations and StrategyPrivate Placements and Financing
Danaher Establishes New $5 Billion Revolving Credit Facility
Positive
Apr 17, 2026
On April 16, 2026, Danaher Corporation entered into a new $5.0 billion 364-day revolving credit facility with Bank of America as administrative agent and a syndicate of lenders, expiring April 15, 2027. The unsecured facility, which can be convert...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.